Bibliography
- Biswas P, Nozza S, Scarlatti G, et al. Oral CCR5 inhibitors: will they make it through? Expert Opin Investig Drugs 2006;15(5):451-64
- Biswas P, Tambusi G, Lazzarin A. Access denied? The status of co-receptor inhibition to counter HIV entry. Expert Opin Pharmacother 2007;8(7):923-33
- Dorr P, Westby M, Dobbs S, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005;49(11):4721-32
- Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996;382(6593):722-5
- Westby M, van der Ryst E. CCR5 antagonists: host-targeted antivirals fort he treatment of HIV infection. Antivir Chem Chemother 2005;6(16):339-54
- Lederman M, Penn-Nicholson A, Cho M, Mosier D. Biology of CCR5 and its role on HIV infection and treatment. JAMA 2006(296):815-26
- Hunt P, Harringa P, Huang W, et al. Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J Infect Dis 2006;194:926
- Mayer H, van der Ryst E, Saag M, et al. Safety and efficacy of maraviroc, a novel CCR5 antagonist, when used in combination with optimized background therapy for the treatment of antiretroviral-experienced subjects infected with dual/mixed-tropic HIV-1: 24-week results of a phase 2b exploratory trial [abstract ThLB0215]. XVI International AIDS Conference (IAC); 2006; Toronto
- Fätkenheuer G, Pozniak A, Johnson MA, et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 2005;(11):1170-2
- Lalezari J, Goodrich J, deJesus E, et al. Efficacy and safety of Maraviroc in antiretroviral treatment experienced patients infected with CCR5-tropic HIV-1: 48 week results of MOTIVATE 1. 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2007; Chicago
- Fätkenheuer G. Efficacy and safety of Maraviroc plus optimized background therapy in viraemic, antiretroviral treatment-experienced patients infected with CCR5-tropic HIV-1 in Europe, Australia and North America (MOTIVATE 2): 48-week results. 11th European AIDS Conference (EACS); 2007
- Abel S, van der Ryst E, Muirhead GJ, et al. Pharmacokinetics of single and multiple oral doses of UK-427,857-a novel ccr5 antagonist in healthy volunteers [abstract 547]. 10th Conference on Retroviruses and Opportunistic Infections (CROI); 2003; Boston, USA
- McHale M, et al. Overview of phase 1 and 2a safety and efficacy data of maraviroc (UK-427,857) [abstract no. TuOa0204]. 3rd IAS Conference on HIV Pathogenesis and Treatment; 2005
- Lalezari J, Goodrich J, DeJesus E, et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic ART-experienced patients infected with CCR5-tropic HIV-1: 24-week results of a phase 2b/3 study in the US and Canada [abstract 104bLB]. 14th Conference on Retroviruses and Opportunistic Infections (CROI); 2007; Los Angeles
- Nelson M, Fätkenheuer G, Kounourina I, et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic, ART-experienced patients infected with CCR5-tropic HIV-1 in Europe, Australia, and North America: 24-week results [abstract 104aLB]. 14th Conference on Retroviruses and Opportunistic Infections (CROI); 2007; Los Angeles
- Hardy D, Reynes J, Konourina I, et al. Efficacy and safety of maraviroc plus optimized background therapy in treatment-experienced patients infected with CCR5-tropic HIV-1: 48-week combined analysis of the MOTIVATE studies [poster 792]. 15th Conference on Retroviruses and Opportunistic Infections (CROI); 2008; Boston
- Saag M, Ive P, Heera J, et al. A multicenter, randomized, double-blind, comparative trial of a novel CCR5 antagonist, maraviroc versus efavirenz, both in combination with combivir (zidovudine/lamivudine), for the treatment of antiretroviral-naive subjects infected with R5 HIV 1: week 48 results of the MERIT study [abstract WESS104]. 4th IAS; 2007; Sydney
- Mosley M, Smith-Burchnell C, Mori J, et al. Resistance to the CCR5 antagonist Maraviroc is characterised by dose-response curves that display a reduction in maximal inhibition [abstract 598]. 13th Conference on Retroviruses and Opportunistic Infections (CROI); 2006; Denver
- Pugach P, Marozsan A, Ketas TJ, et al. HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology 2007;361(1):212-28
- Westby M, Lewis M, Whitcomb J, et al. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 2006; 80(10):4909-20
- Steel HM. Special presentation on aplaviroc-related hepatotoxicity. 10th European AIDS Conference (EACS); 2005; Dublin
- Mayer H. Case study of a patient with serious hepatotoxicity in maraviroc IIB/III trial. Targeting HIV Entry – First International Workshop; 2005; Bethesda
- Clotet B. CCR5 inhibitors: promising yet challenging. J Infect Dis 2007;196:178
- Reyes G. Development of CCR5 antagonists as a new class of anti-HIV therapeutic [abstract L11]. 8th Conference on Retroviruses and Opportunistic Infections (CROI); 2001; Chicago
- Davis JD, Hackman F, Layton G, et al. Effect of single doses of maraviroc on the QT/QTc interval in healthy subjects. Br J Clin Pharmacol 2008;65(Suppl 1):68-75
- Schering-Plough Corp. Schering-Plough provides an update on Phase II study of vicriviroc: study continues in HIV-treatment experienced patients. Press release 3 March 2006. Available from: www.schering-plough.com
- Gulick R, Su Z, Flexner C, et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: AIDS Clinical Trials Group 5211. J Infect Dis 2007;196(2):304-12
- Dean M, Jacobson L, McFarlane G, et al. Reduced risk of AIDS lymphoma in individuals heterozygous for the CCR5- 32 mutation. Cancer Res 1999;59:3561-4
- Gulick R, Su Z, Flexner C, et al. ACTG 5211: phase II study of the safety and efficacy of vicriviroc (VCV) in HIV-infected treatment-experienced subjects: 48 week results [abstract TUAB102]. 4th IAS Conference; 2007
- Glass WG, McDermott DH, Lim JK, et al. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med 2006;203(1):35-40
- Ahlenstiel G, Woitas R, Rockstroh JK, Spengler U. CC chemokin receptor 5 (CCR5) in hepatitis C-at the crossroads of the antiviral immune response? J Antimicrob Chemother 2004;53:895-8
- Ayoub A, van der Ryst E, Turner K, McHale M. A review of the markers of immune function during the Maraviroc phase 1 and 2a studies [abstract 509]. 14th Conference on Retrovirsuses and Opportunistic Infections (CROI); 2007; Los Angeles
- Peters C, Kawabata T, Syntin P, et al. Assessment of immunotoxic potential of Maraviroc in cynomolgus monkeys [abstract 1100]. 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2005; Washington
- Karlsson I, Antonsson L, Shi Y, et al. HIV biological variability unveiled: frequent isolations and chimeric receptors reveal unprecedented variation of coreceptor use. AIDS 2003;17:2561-9
- Karlsson U, Antonsson L, Owman C, et al. Coreceptor use in paired plasma and cerebrospinal fluid HIV-1 isolates [abstract H-246]. 46th ICAAC; 2006; San Francisco
- Goodkin K, Vitiello B, Lyman WD, et al. Cerebrospinal and peripheral human immunodeficiency virus type 1 load in a multisite, randomized, double-blind, placebo-controlled trial of D-Ala1-peptide T-amide for HIV-1-associated cognitive-motor impairment. J Neurovirol 2006;(12):178-89
- Abel S, Taylor-Worth R, Ridgway C, et al. Effect of boosted tipranavir on the pharmacokinetics of Maraviroc (UK 427,857) in healthy volunteers [abstract LBPE4.3/15]. 10th European AIDS Conference (EACS); 2005; Dublin
- Abel S, Russell D, Ridgway C, Muirhead G. Overview of the drug-drug interaction data for maraviroc [abstract 76]. 6th International Workshop on Clinical Pharmacology of HIV Therapy; 2005; Quebec, Canada
- Muirhead G, Pozniak A, Gazzard B, et al. A novel probe drug interaction study to investigate the effect of selected ARV combinations on the pharmacokinetics of a single oral dose of UK-427,857 in HIV + ve subjects [abstract 663]. 12th Conference on Retroviruses and Opportunistic Infections (CROI); 2005; Boston
- Abel S, Russell D, Ridgway C et al. Effect of CCR5 antagonist UK 427,857 on the pharmacokinetics of CYP3A4 substrates in healthy volunteers. 5th International Workshop on Clinical Pharmacology of HIV Therapy (abstract 5.7); 2004; Rome, Italy
- Abel S, Whitlock L, Ridgway C, et al. Effect of UK-427,857 on the pharmacokinetics of oral contraceptive steroids, and the pharmacokinetics of UK-427, 857 in young women. Proceedings of the 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 14 – 17 September 2003; Chicago. Abstract A-1619
- Pfizer. Data on file. FDA Antiviral Drugs Advisory Committee (AVDAC) meeting held 24 April 2007. Available from: http://www.fda.gov/ohrms/dockets/ac/cder07.htm#AntiviralDrugs
- Jenkins T, Abel S, Russell D, et al. The effect of P450 inducers on the pharmacokinetics of CCR5 antagonist UK-427,857 in healthy volunteers. Program and abstracts of the 5th International Workshop on Clinical Pharmacology of HIV Therapy. 1 – 3 April 2004; Rome, Italy. Abstract 5.4
- US Department of Health and Human Services, Federal Food and Drug Administration (FDA). Medication guide: highlights of precribing information, Selzentry (maraviroc) tablets. Initial US approval 2007. Available from: www.fda.gov
- US Department of Health and Human Services, Federal Food and Drug Administration (FDA). FDA approves new HIV-drug: raltegravir tablets used in combination with other antiretroviral agents. FDA news for immediate release; 16 October 2007. Available from: www.fda.gov
- Grinsztejn B, Nguyen B, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment experienced patients with multidrug-resistant virus: a phase II randomized controlled trial. Lancet 2007;369(9569):1261-9
- Cooper D, Gatell J, Rockstroh J, et al. 48-Week results from BENCHMRK-1, a phase III study of raltegravir (RAL) in patients failing antiretroviral therapy (ART) with triple-class resistant HIV-1. 15th Conference on Retroviruses and Opportunistic Infections (CROI); 2008; Boston
- Steigbigel R, Kumar R, Eron J, et al. 48-Week results from BENCHMRK-2, a phase III study of raltegravir (RAL) in patients failing antiretroviral therapy (ART) with triple-class resistant HIV-1. 15th Conference on Retroviruses and Opportunistic Infections (CROI); 2008; Boston
- Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007;370(9581):29-38
- Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007;370(9581):39-48
- US Department of Health and Human Services, Federal Food and Drug Administration (FDA). FDA approves new HIV drug after priority review. Etravirine tablets used in combination with other antiretroviral agents. FDA news for immediate release; 18 January 2008. Available from: www.fda.gov
- Gruzdev B, Rakhmanova A, Doubovskaya E, et al. A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects. AIDS 2003;(17):2487-94
- Sankatsing SUC, Weverling G, Peeters M, et al. TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen. AIDS 2003;17(18):2623-7